These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 36344070)
1. Novel Applications of Biomarkers and Personalized Medicine in Cystic Fibrosis. Guimbellot JS; Nichols DP; Brewington JJ Clin Chest Med; 2022 Dec; 43(4):617-630. PubMed ID: 36344070 [TBL] [Abstract][Full Text] [Related]
2. Patient personalized translational tools in cystic fibrosis to transform data from bench to bed-side and back. Arora K; Yang F; Brewington J; McPhail G; Cortez AR; Sundaram N; Ramananda Y; Ogden H; Helmrath M; Clancy JP; Naren AP Am J Physiol Gastrointest Liver Physiol; 2021 Jun; 320(6):G1123-G1130. PubMed ID: 33949881 [TBL] [Abstract][Full Text] [Related]
3. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations. Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function. Arora K; Naren AP Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081 [TBL] [Abstract][Full Text] [Related]
5. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date. Becq F Drugs; 2010 Feb; 70(3):241-59. PubMed ID: 20166764 [TBL] [Abstract][Full Text] [Related]
6. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine. Januska MN; Marx L; Walker PA; Berdella MN; Langfelder-Schwind E J Genet Couns; 2020 Aug; 29(4):607-615. PubMed ID: 32227567 [TBL] [Abstract][Full Text] [Related]
7. Personalized medicine in cystic fibrosis: genistein supplementation as a treatment option for patients with a rare S1045Y-CFTR mutation. Arora K; Yarlagadda S; Zhang W; Moon C; Bouquet E; Srinivasan S; Li C; Stokes DC; Naren AP Am J Physiol Lung Cell Mol Physiol; 2016 Aug; 311(2):L364-74. PubMed ID: 27261451 [TBL] [Abstract][Full Text] [Related]
8. A new era of personalized medicine for cystic fibrosis - at last! Quon BS; Wilcox PG Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544 [TBL] [Abstract][Full Text] [Related]
18. Discovery of CFTR modulators for the treatment of cystic fibrosis. Lopes-Pacheco M; Pedemonte N; Veit G Expert Opin Drug Discov; 2021 Aug; 16(8):897-913. PubMed ID: 33823716 [TBL] [Abstract][Full Text] [Related]
19. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis. Cuyx S; De Boeck K Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727 [TBL] [Abstract][Full Text] [Related]
20. One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies. Ensinck MM; Carlon MS Cells; 2022 Jun; 11(12):. PubMed ID: 35740997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]